Hetero launches ‘Favipiravir’ to treat Coronavirus


Hetero launches Favipiravir in India under the brand ‘Favivir’ to treat Coronavirus.

Hetero group has declared the launch of its generic Favipiravir drug in India under the brand ‘Favivir’ for the treatment of mild to moderate Covid-19 patients, getting the approvals from the Drug Controller General of India (DCGI) to manufacture and market the generic drug for Covid-19.

Favipiravir is the second drug manufactured by Hetero after Covifor, which is the generic version of Remdesivir injection to be carried out intravenously in a hospital for the treatment of severe Covid-19, with the license from Gilead Sciences. The product is available from July 29 at all retail medical outlets across the country and will be sold only on prescription by the doctor.

The generic pharmaceuticals group with its headquarters at Hyderabad, which is also the world’s largest producer of antiretroviral drugs, said Favivir drug makes better treatment accessibility to a notable amount of Covid-19 patient population, that mostly supports mild to moderate symptoms. It is an oral antiviral medication or drug that has shown it’s positive clinical outcomes. Favipiravir was actually developed by Japan’s Fujifilm under the brand name Avigan for treating influenza.

Favipiravir drug is to be sold at Rs 59 per tablet and will be marketed and distributed by the Hetero Healthcare, said Hetero Group. The company added that the product will be made available at all retail medical outlets and hospital pharmacies across the country to be sold on prescription-based.

The company added further, that the drug is being manufactured at its world-class management, which has been permitted by the stringent global regulatory authorities such as the USFDA and the EU, among others. This was also advocated by strong vertical integration capabilities.

Hetero, has its interest across active pharmaceutical ingredients, biosimilars, generics, custom pharmaceutical services, and branded generics. It has 36 currently manufacturing facilities situated at different locations of the world with approvals from global regulatory authorities.

The portfolio of the Hetero group includes more than 300 products surrounding key therapeutic categories that include HIV/AIDS, cardiovascular, oncology, neurology, hepatitis, urology, diabetes, ophthalmology, hepatology, and immunology, among others. The company marks its presence in around 126 countries across the globe.